Cytochromes P450 and UDP-glucuronosyltransferases as hepatocellular autoantigens

Bailliere's Clinical Gastroenterology

Volumn 10, Issue 3, 1996, Pages 501-532

  Obermayer Straub, Petra ^a   Manns, Michael P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYTOCHROME P450; DIHYDRALAZINE; GLUCURONOSYLTRANSFERASE; HALOTHANE; HLA B ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; TIENILIC ACID;

AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; CELLULAR IMMUNITY; CHRONIC HEPATITIS; DELTA AGENT HEPATITIS; DRUG ACTIVATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG STRUCTURE; HEPATITIS; HEPATITIS C; HUMAN; HYPERGAMMAGLOBULINEMIA; LIVER CELL; LIVER REGENERATION; LIVER TOXICITY; METABOLIC ACTIVATION; MULTIGENE FAMILY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; T LYMPHOCYTE;

EID: 0029809613     PISSN: 09503528     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-3528(96)90055-X     Document Type: Article

References (139)

1. Aaltonen J, Bjorses P, Sadkuijl L et al (1994) An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type 1 assigned to chromosome 21. Nature Genetics 8: 83-87.
2. Agnello V, Chung RT & Kaplan L (1992) A role of hepatitis C virus infection in type II cryoglobulinemia. New England Journal of Medicine 19: 1490.
3. Ahonen P, Miettinen A & Perheentupa J (1987) Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure. Journal of Clinical Endocrinology and Metabolism 64: 494-500.
4. Ahonen P, Koskimies S, Lokki ML et al (1988) The expression of autoimmune polyglandular disease type I appears associated with several HLA-A antigens but not with HLA-DR. Journal of Clinical Endocrinology and Metabolism 66: 1152-1157.
5. Ahonen P, Myllärniemi S, Sipilä I & Perheentupa J (1990) Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. New England Journal of Medicine 322: 1829-1836.
6. Arulantham K, Dwyer JM, Genel M et al (1979) Evidence for defective immunoregulation in the syndrome of familial candidiasis endocrinopathy. New England Journal of Medicine 300: 164-168.
7. Beaune PH, Bourdi M, Belloc C et al (1993) Immunotoxicology and expression of human cytochrome P450 in microorganisms. Toxicology 82: 53-60.
8. Beaune PH, Pessayre D, Dansette P et al (1994) Autoantibodies against cytochromes P450: role in human diseases. Advances in Pharmacology 30: 199-245.
9. Bernuau J, Mallet L & Benhamon JP (1981) Hepatotoxicite due a l'acide tienilique. Gastroenterologie Clinique et Biologique 5: 692-693.
10. Bianchi FB, Lenzi, Cassani F et al (1993) Immunology and autoimmunity in hepatis C. In Meyer zum Büschenfelde KH, Hoofnagle J, Manns M (eds) Immunology and the Liver. pp 102-104. Dordrecht: Kluwer Academic Publishers.
11. Boccaccio F, Attali P, Nataf J et al (1987) Hepatite aigue a la dihydralazine. Gastroenterologie Clinique et Biologique 11: 614.
12. Bock KW (1992) Metabolic polymorphisms affecting activation of toxic and mutagenic arylamines. Trends in Pharmacological Science 13: 223-226.
13. Bourdi M, Larrey D, Nataf J et al (1990) Anti-liver endoplasmatic reticulum autoantibodies are directed against human cytochrome P450 IA2: a specific marker of dihydralazine-induced hepatitis. Journal of Clinical Investigation 85: 1967-1973.
14. Bourdi M, Gautier JC, Micheva J et al (1992) Anti-liver microsomes autoantibodies and dihydralazune induced hepatitis: specificity of autoantibodies and inductive capacity of the drug. Molecular Pharmacology 42: 280-285.
15. Bourdi M, Tinel M, Beaune PH & Pessayre D (1994) Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-P450 1A2 autoantibodies. Molecular Pharmacology 45: 1287-1295.
16. Burchell B, Nebert DW, Nelson DR et al (1991) The UDP-glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA and Cell Biology 10: 487-494.
17. Burchell B, Coughtree MWH & Jansen PLM (1994) Function and regulation of UDP-glucuronosyltransferase genes in health and liver disease: report on the seventh international workshop on glucuronidation, September 1993, Pitlochry, Scotland. Hepatology 20: 1622-1630.
18. Butler LE, Thomassen D, Martin JL et al (1992) The calcium binding protein calreticulin is covalently modified in rat liver by a reactive metabolite of the inhalation anaesthetic halothane. Chemical Research in Toxicology 5: 406-410.
19. Cacoub P, Lunel-Fabiani F, Huong Du LT et al (1992) Polyarteritis nodosa and hepatitis C infection. Annals of Internal Medicine 116: 605-606.
20. Christen U, Jeno P & Gut J (1993) Halothane metabolism: the dihydrolipoamide acetyltransferase subunit of the pyruvate dehydrogenase complex mimics trifluoroacetyl-protein adducts. Biochemistry 32: 1492-1499.
21. Clemente MG, Obermayer-Straub P, Meloni A et al (1995) Autoantibodies against cytochrome P450 1A2 in a patient with liver disease in autoimmune polyendocrine syndrome type 1. 30th Annual Meeting of the German Association of the Study of the Liver, Kopenhagen. Journal of Hepatology (in press).
22. Codoner-Franch P, Paradis P, Guenguen M et al (1989) A new antigen recognized by anti-liver-microsome antibody (LKMA). Clinical and Experimental Immunology 159: 542-547.
23. Crivelli O, Lavarini C, Chiaberge E et al (1983) Microsomal autoantibodies in chronic infection with HBsAg associated delta (d) agent. Clinical and Experimental Immunology 54: 232-238.
24. DeCastro M, Sanchez J, Herrera JF et al (1993) Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 17: 551-557.
25. De Lemos-Chiarandini C, Alvarez F, Bernard O et al (1987a) Determination of the membrane topology of the phenobarbital-inducible rat liver cytochrome P450 isoenzyme PB-4 using site-specific antibodies. Journal of Cell Biology 104: 209-219.
26. De Lemos-Chiarandini C, Alvarez F et al (1987b) Anti-Liver-Kidney microsome antibody is a marker for the rat hepatocyte endoplasmic reticulum Hepatology 7: 468-475.
27. Dienstag IL (1990) Hepatitis non-A, non-B: C at last. Gastroenterology 99: 1177-1180.
28. Donaldson PT, Doherty DG, Hayliar KM et al (1991) Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR 4 and A1-B8-Dr-3 are independent risk factors. Hepatology 13: 701-706.
29. Duclos-Vallee JC, Hajoui O, Yamamoto AM, Jacqz-Aigrain E & Alvarez F (1995) Conformational epitopes on Cyp 2D6 are recognized by liver/kidney microsomal antibodies. Gastroenterology 108: 470-476.
30. Durazzo M, Philipp T, van Pelt FNAM et al (1995) Heterogeneity of microsomal autoantibodies (LKM) in chronic hepatitis C and D virus infection. Gastroenterology 108: 455-462.
31. Fargion S, Peperno A, Cappellini MD et al (1992) Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 16: 1322-1326.
32. Eade OE, Grice D, Krawit EL et al (1981) HLA A and b locus antigens in patients with unexplained hepatitis following halothane anaesthesia. Tissue Antigens 17: 428-432.
33. Ferri C, Greco F, Longombardo G et al (1991) association between hepatitis C virus and mixed cryoglobulinemia. Clinical and Experimental Rheumatology 9: 621-624.
34. Fevery J (1981) Pathogenesis of Gilbert's syndrome. European Journal of Clinical Investigations 11: 417-418.
35. Freudenberg J, Baumann H, Arnold W et al (1977) HLA in different forms of chronic active hepatitis: a comparison between adult patients and children. Digestion 15: 260-270.
36. Fussey SPM, Guest JR, James OFW et al (1988) Identification and analysis of the major autoantigens in primary biliary cirrhosis. Proceedings of the National Academy of Science of the USA 85: 8654-8658.
37. Gonzalez FJ, Skoda RC, Kimura S et al (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331: 442-446.
38. Gruenke LD, Konopka DR & Koop Drand Waskell LA (1988) Characterization of halothane oxidation by hepatic microsomes and purified cytochrome P450 using gas chromatographic mass spectometric assay. Journal of Pharmacological and Experimental Therapies 246: 454-459.
39. Guengerich FP (1993) Cytochrome P450 enzymes. American Scientist 81: 440-447.
40. Guenguen M, Yamamoto AM, Bernd O & Alvarez F (1989) Anti-liver kidney microsome antibody type 1 recognizes human cytochrome P450 db1. Biochemical and Biophysical Research Communications 159: 542-547.
41. Gut J, Christen U, Huwyler J et al (1992) Molecular mimicry of trifluoroacetylated human liver protein adducts by constitutive proteins and immunochemical evidence for its impairment in halothane hepatitis. European Journal of Biochemistry 210: 569-576.
42. Gut J, Christen U & Huwyler J (1993) Mechanisms of halothane toxicity: novel insights. Pharmacological Therapy 58: 133-158.
43. Haddad J, Deny P, Munz-Gotheil C et al (1992) Lymphocyticsialadenitis of Sjörgen's syndrome associated with chronic hepatitis c virus liver disease. Lancet 339: 321-323.
44. Hoft RH, Bunker JP, Goodman HI & Gregory PB (1981) Halothane hepatitis in three pairs of closely related women. New England Journal of Medicine 304: 1023-1024.
45. Homberg JC, Andre C & Abuaf N (1984) A new anit-liver/kidney-microsome antibody (anti-LKM2) in tienilic induced hepatitis. Clinical and Experimental Immunology 55: 561-570.
46. Homberg JC, Abuaf N, Hemly-Khalid et al (1985) Drug induced hepatitis associated with anticytoplasmic organelle autoantibodies. Hepatology 5: 722-725.
47. Iyanagi T, Haniu M, Sogawa K et al (1986) Cloning and characterization of cDNA ending methylcholanthrene inducible rat mRNA for UDP-glucuronosyltransferase. Journal of Biological Chemistry 261: 15 607-15 614.
48. Jarasch ED, Kartenberg J, Bruder G et al (1979) B-types cytochromes in plasma membrane isolated from rat liver, in comparison with those from endomembranes. Journal of Cell Biology 80: 37-52.
49. Johnson RJ & McFarlane IG (1993) Meeting report: international autoimmune hepatitis group. Hepatology 18: 998-1005.
50. Johnson RJ, Gretch DR, Yamabe et al (1993) Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. New England Journal of Medicine 18: 465-470.
51. Kenna JG & van Pelt FNAM (1994) The metabolism and toxicity of inhaled anaesthetic agents. Anaesthetical and Pharmacological Reviews 2: 29-42.
52. Kenna JG, Martin JL, Satoh H & Pohl LR (1990a) Purification of trifluoroacetylated protein antigens from livers of halothane-treated rats. European Journal of Pharmacology 183: 1139-1140.
53. Kenna JG, Martin JL, Satoh H & Pohl LR (1990b) Factors affecting the expression of trifluoroacetylated liver microsomal protein neoantigens in rats treated with halothane. Drug Metabolism and Disposition 18: 788-793.
54. Knights KM, Gourlay GK, Gibson RA & Cousins MJ (1988) Halothane induced hepatic necrosis in rats. The role of in vivo lipid peroxiodation. Pharmacology and Toxicology 63: 327-332.
55. Koop DR (1992) Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB Journal 6: 724-730.
56. Krohn K, Uibo R, Aavik E et al (1992) Identification by molecular cloning of an autoantigen associated with Addison's Disease as steroid 17a-hydroxylase. Lancet 339: 770-773.
57. Kunze, KD, Porst H & Tschöppel L (1985) Morphologie und Pathogenese von Leberschäden durch Dihydralazin, Propanolol und Ketophenylbutazon. Zentralblatt der Allgemeinen Pathologie und Anatomie 130: 509-518.
58. Lecoeur S, Bonierbale E, Challine D et al (1994) Specificity of in vitro covalent binding of tienilic acid metabolites to comparison with two directly hepatotoxic drugs. Chemical Research in Toxicology 7: 434-442.
59. Lenzi M, Bianchi B, Casani F et al (1984) Liver cell surface expression of the antigen reacting with liver-kidney microsomal antibody (LKM) Clinical and Experimental Immunology 55: 36-40.
60. Lenzi M, Johnson PJ, McFarlane IG et al (1991) Antibodies to hepatitis C virus in autoimmune liver disease; evidence for geographical heterogeneity. Lancet 338: 277-280.
61. Lenzi M, Mantovani W, Cataleta M et al (1992) HLA typing in autoimmune hepatitis (AI-CAH) type 2. Journal of Hepatology 16: 59.
62. Loeper J, Descartoire V, Maurice M et al (1990) Presence of functional cytochrome P450 on isolated rat hepatocyte plasma membrane. Hepatology 11: 850-858.
63. Loeper J, Descartoire V, Maurice M et al (1993) Cytochromes P450 in human hepatocyte plasma membrane: recognition by several autoantibodies. Gastroenterology 104: 203-216.
64. Löhr H, Manns M, Hyriasoulis et al (1991) Clonal analysis of liver infdiltrating cells in patients with chronic active hepatitis (AI-CAH). Clinical and Experimental Immunology 84: 297-302.
65. Lopez-Garcia MP, Dansette PM, Valadon P et al (1993) Human liver P450s expressed in yeast as tools for reactive metabolite formation studies. Oxidative activation of tienilic acid by cytochrome P450 2C9 and P450 2C10. European Journal of Biochemistry 213: 223-232.
66. Lunel F, Abuaf N, Frangeul L et al (1992) Liver-kidney microsomes antibody type 1 and hepatitis C virus infection. Hepatology 16: 630-636.
67. Ma Y, Lenzi M, Gäken J et al (1992) The target antigen of liver kidney microsomal antibody is different in type II autoimmune chronic active hepatitis and chronic hepatitic C virus infection. Journal of Hepatology 16: 4.
68. Mackay IR (1991) Autoimmune hepatitis: the realities and the uncertainties. Gastroenterolerology of Japan 28: 102-108.
69. Mackay IR & Morris PJ (1972) Association of autoimmune chronic hepatitis with HLA-A1-B8. Lancet ii: 793-795.
70. Mackay IR & Tait BD (1980) HLA association with autoimmune type chronic active hepatitis: identification of B8-DRw3 haplotype by family studies. Gastroenterology 79: 95-98.
71. Manns MP (1991) Cytoplasmic autoantigens in autoimmune hepatitis: molecular analysis and clinical relevance. Seminars in Liver Disease 11: 205-214.
72. Manns M & Krüger M (1994) Genetics in liver diseases. Gastroenterology 106: 1676-1697.
73. Manns M, Johnson EF, Griffin KJ et al (1989) The major target antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450 db1. Journal of Clinical Investigation 83: 1066-1072.
74. Manns MP, Griffin KJ, Quattrochi L et al (1990a) Identification of cytochrome P450 IA2 as a human autoantigen. Archives of Biochemistry and Biophysics 280: 229-232.
75. Manns M, Zanger U, Gerken G et al (1990b) Patients with type II autoimmune hepatitis express functionally intact cytochrome P450 db1 that is inhibited by LKM1 autoantibodies in vitro but not in vivo. Hepatology 12: 127-132.
76. Manns MP, Griffin KJ, Sullivan KF & Johnson EF (1991) LKM1 autoantibodies rexcognize a short linear sequence in P450 IID6, a cytochrome P450 monooxygenase. Journal of Clinical Investigation 88: 1370-1378.
77. Michel G, Ritter A, Gerken G et al (1992) Anti-GOR and hepatitis C virus in autoimmune liver diseases. Lancet 339: 267-269.
78. Michele TM, Fleckenstein J, Sgrignoli AR & Tuluvath PJ (1994) Chronic active hepatitis in the type I polyglandular autoimmune syndrome. Postgraduate Medical Journal 70: 128-131.
79. Michitaka K, Durazzo M, Tillmann H et al (1994) Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology 106: 1603-1610.
80. Mishiro S, Hoshi Y, Takeda K et al (1990) Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process. Lancet 336: 1400-1403.
81. Nataf J, Bernuau J, Larrey D et al (1986) A new anti-liver microsome antibody: a specific marker of dihydralazine-induced hepatitis. Gastroenterology 90: 1751.
82. Nebert DW & McKinnon RA (1994) Cytochrome P450: evolution and functional diversity. Progress in Liver Diseases 12: 63-97.
83. Nelson DR & Strobel HW (1987) The evolution of cytochrome P450 proteins. Molecular Biology and Evolution 4: 572-593.
84. Nelson DR, Kamataki T, Waxman DJ et al (1993) The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomencalture. DNA and Cell Biology 12: 1-51.
85. Neufeld M, Maclaren N & Blizzard R (1980) Autoimmune polyglandular syndromes. Pediatric Annals 9: 154-162.
86. Paronetto F & Popper H (1970) Lymphocyte stimulation induced by halothane in patients with hepatitis following exposure to halothane. New England Journal of Medicine 283: 277-280.
87. Pessayre D (1993) Toxic and immune mechanisms leading to acute and subacute drug induced liver injury. In Miguet JP & Dhumeaux D (eds), Progress in Hepatology pp 23-39. Paris: John Libbey Eurotext.
88. Peterson P & Krohn JE (1994) Mapping of B cell epitopes on steroid 17a-hydroxylase, an autoantigen in autoimmune polyglandular syndrome type I. Clinical and Experimental Immunology 98: 104-109.
89. Philipp T, Durazzo M, Trautwein C et al (1994) LKM-3 autoantibodies in chronic hepatitis D recognize the UDP-glucuronosyltransferases. Lancet 344: 578-581.
90. Plummer JL, Beckwith AJL, Bastin FN et al (1982) Free radical formation in vivo and hepatoxicity due to anaesthesia with halothane. Anaesthesiology 57: 160-166.
91. Pohl LR, Thomassen D, Pumford NR et al (1991) Hapten carrier conjungates associated with halothane hepatitis. Advances in Experimental and Biological Medicine 283: 111-120.
92. Pumford NR, Martin BM, Thomassen D et al (1993) Serum antibodies from halothane hepatitis patients react with the rat endoplamic reticulum protein ERp72. Chemical Research in Toxicology 6: 609-615.
93. Ray DC & Drummond GB (1991) Halothane hepatitis. British Journal of Anaesthesiology 67: 84-89.
94. Reinhardt M, Machnik G, Krombholz B & Jashn G (1985) Die sogenannte Dihydralazin-Hepatitis. Ein Beitrag zur Pathogenese. Deutsche Zeitschrift der Verdauugs- und Stoffwechselkrankheiten 45: 283-294.
95. Riley WJ (1992) Autoimmune polyglandular syndromes. Hormone Research 38 (supplement 2): 9-15.
96. Ritter JK, Chen F, Sheen YY et al (1992) A novel complex locus UGT1 encodes human bilirubin, phenol and other UDP-glucuronosyltransferase isozymes with identical carbonyl termini. Journal of Biological Chemistry 267: 3257-3261.
97. Rizzetto M, Swana C & Doniach D (1973) Microsomal antibodies active chronic hepatitis and other disorders. Clinical and Experimental Immunology 15: 331-344.
98. Robin MA, Maratrat M, Loeper-J et al (1995) Cytochrome P4502B follows a vesicular route to the plasma membrane in cultured rat hepatocytes. Gastroenterology 108: 1110-1123.
99. Roschlau G (1983) Hepatitis mit konfluierenden Nekrosen durch Dihydralazin (Depressan) Zentalblatt für Allgemeine Pathologie und Anatomie 127: 385-393.
100. Roschlau G (1986) Virushepatitis gegen Arzneimittelhepatitis. Zeitschrift für Klinische Medizin 41: 817-819.
101. Roy Chowdhury J, Wolkoff AW, Arias IM et al (1989) Inherited jaundice and disorders of bilirubin metabolism. In Scriver CR, Beaudet AL, Sly WS & Valle D (eds), The Metabolic Basis of Inherited Disease, 6th edn, pp 1085-1094. New York: Mc Graw-Hill.
102. Sacher M, Blumel P, Thaler H & Manns M (1990) Chronic active hepatitis associated with vitiligo, nail dystrophy, alopecia and a new variant of LKM antibodies. Journal of Hepatology 10: 364-369.
103. Schröder LW, Siegmund W, Schneider T et al (1986) Zur Blutdruckwirksamkeit ausgewähler Dihydralazinmetabolite. Pharmazie 41: 439.
104. Scully LJ, Toze C, Sengar DPS & Goldstein R (1993) Early-onset autoimmune hepatitis is associated with a C4A gene deletion. Gastroenterology 104: 1478-1484.
105. Seki T, Kiyosawa K, Inoko H & Ota M (1990) Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology 12: 1300-1304.
106. Siegmund W, Franke G, Biebler et al (1985) The influence of the acetylator phenotype on the clinical use of dihydralazine. International Journal of Clinical Pharmacology and Therapeutic Toxicology 23: S74-S78.
107. Sipes IG, Gandolfi J, Pohl LR et al (1980) Comparision of the biotransformation and hepatotoxicity of halothane and deuterated halothane Journal of Experimental Therapy 214: 716-720.
108. Sindelar WF, Tralka TS & Gibbs PS (1982) Evidence for acute cellular changes in human hepatocytes during anaesthesia with halohgenated agents: an electron microscopic study. Surgery 92: 520-527.
109. Skoda RC, Gonzalez FJ, Derrierre A & Meyer UA (1988) Two mutant alleles of the human P450 db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proceedings of the National Academy of Sciences of the USA 85: 5240-5243.
110. Smith GC, Kenna JG, Harrison DJ et al (1993) autoantibodies to hepatic microsomal carboxylesterase in halothane hepatitis. Lancet 342: 963-964.
111. Song YH, Connor EL, Muir A et al (1994) Autoantibody epitope mapping in autoimmune Addison's Disease. Journal of Clinical Endocrinology and Metabolism 78: 1108-1112.
112. Stacieki P & Oesch F (1980) Distribution of enzymes involved in metabolism of polycyclic aromatic hydrocarbons among rat liver endomembranes and plasma membranes. European Journal of Cell Biology 21: 79-92.
113. Straub P, Philipp T, Lamb JG et al (1994) Molecular characterization of a microsomal antigen in hepatitis D. 45th Annual Meeting of the American Association for the Study of Liver Diseases. Hepatology 20: 427.
114. Stricker BHC (1992) Drug-Induced Hepatic Injury Amsterdam: Elsevier.
115. Tait B, Mackay IR, Board PH et al (1989) HLA-AL -B8, -DR3 extended haplotypes in autoimmune chronic hepatitis. Gastroenterology 97: 479-481.
116. Thomassen D, Martin BM, Martin JL et al (1989) The role of a stress protein in the development of drug induced allergic response. European Journal of Pharmacology 183: 1138-1139.
117. Thomsen MS, Loft S, Roberts DW & Poulsen HE (1995) Cytochrome P450 2E1 inhibition by propylene glycol prevents acetaminophen (paracetamol) hepatotoxicizy in mice without cytochrome P450 1A2 inhibition. Pharmacology and Toxicology 76: 395-399.
118. Tran A, Quaranta JF, Benzaken S et al (1993) High prevalence of thyrois antibodies in a prospective series of patients with chronic hepatitis C. Hepatology 18: 253-257.
119. Trautwein C, Ramadori G, Gerken G et al (1992) Regulation of cytochrome P450 2D by acute phase mediators in C3H/HeJ mice. Biochemical and Biophysical Research Communications 182: 617-623.
120. Trautwein C, Gerken G, Meyer zum Büschenfelde KH & Manns MP (1993) Lack of surface expression for the B-cell autoepitope of cytochrome P450 2D6 evidenced by flow cytometry. Zeitschrift für Gastroenterologie 31: 225-230.
121. Trowell J, Peto R & Crampton Smith A (1975) Controlled trial of repeated halothane anaesthetics in patients with carcinoma of the uterine cervix treated with radium. Lancet i: 821-824.
122. Trudell JR, Ardies CM & Anderson WR (1991) Antibodies raised against trifluoroacetyl-protein adducts bind to N-trifluoroacetyl-phosphatidylethanolamine in hexagonal phase phospholipid micelles. Journal of Pharmacological and Experimental Therapy 257: 657-662.
123. Uibo R, Aavik E, Peterson P et al (1994a) Autoantibodies to cytochrome P450 enzymes P450 see, P450 c17 and P450 c21 in Autoimmune Polyglandular Diseases types I and II and in isolated Addison's disease. Journal of Clinical Endocrinology and Metabolism 78: 323-328.
124. Uibo R, Perheentupa J, Ovod V & Krohn KJE (1994b) Characterization of adrenal autoantigens recognized by serta from patients with autoimmune polyglandular syndrome (APS) type 1. Journal of Autoimmunity 7: 399-411.
125. Van Pelt FN, Straub P & Manns MP(1995) Molecular basis of drug-induced immunological liver injury. Seminars in Liver Disease 15: 283-300.
126. Vergani D, Wells L, Larcher VF et al (1985) Genetically determined low C4: a predisposing factor to autoimmune chronic active hepatitis. Lancet ii: 294-298.
127. Walton B, Simpson BR, Strunin L et al (1976) Unexplained hepatitis following halothane. British Medical Journal 1: 1171-1176.
128. Winqvist O, Karlsson FA & Kämpe O (1992) 21-hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet 339: 1559-1562.
129. Winqvist O, Gustafsson J, Rorsman F et al (1994) Two different cytochrome P450 enzymes are the adrenal antigens in autoimmune polyendocrine syndrome type 1 and addison's disease. Journal of Clinical Investigation 92: 2377-2385
130. Winqvist O, Gebre-Mehedin G, Gustafsson et al (1995) Identification of the main gonadal autoantigens in patients with adrenal insufficiency and associated ovarian failure. Journal of Clinical Endocrinology and Metabolism 80: 1717-1723.
131. Wittingham S, Mathews JD, Schanfield MS et al (1981) Interaction of HLA and Gm in autoimmune chronic active hepatitis. Clinical and Experimental Immunology 26: 102-108.
132. Wright R, Bade OE, Chisolm M et al (1975) Controlled prospective study of the effect on liver function of multiple exposures to halothane. Lancet i: 817-820.
133. Wu D & Cederbaum AI (1992) Presence of functionally active cytochrome P4502E1 in the plasma membrane of rat hepatocytes. Hepatology 15: 515-524.
134. Yamamoto AM, Mura C, De Lemos-Chiardini C et al (1993a) Cytochrome P450 2D6 recognized by LKM1 antibody is not expressed on the surface of hepatocytes. Clinical and Experimental Immunology 92: 381-390.
135. Yamamoto AM, Cresteil D, Boniface O et al (1993b) Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1) European Journal of Immunology 23: 1105-1111.
136. Yamamoto AM, Crestil D, Homberg JC & Alvarez F (1993c) Characterization of anti-liver-kidney microsome antibodiy (anti-LKM1) from hepatitis C virus positive and negative sera. Gastroenterology 104: 1762-1767.
137. Zanger UM, Hauri HP, Loeper J et al (1988) Antibodies against human cytochrome P450db1 in autoimmune hepatitis type II. Proceedings of the National Academy of Sciences USA 85: 8256-8260.
138. Zimmerman HJ (1978) In Zimmerman HJ (ed.), Hepatotoxiocity. The Adverse Effects of Drugs and Other Chemicals on the Liver. New York: Appleton Century Crofts.
139. Zimmerman HJ, Lewis JH, Ishak KG & Maddrey W (1984) Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 4: 315-323.